Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;105(4):888-894.
doi: 10.3324/haematol.2018.214239. Epub 2020 Mar 5.

Glanzmann thrombasthenia: genetic basis and clinical correlates

Juliana Perez Botero  1 , Kristy Lee  2 , Brian R Branchford  3 , Paul F Bray  4 , Kathleen Freson  5 , Michele P Lambert  6 , Minjie Luo  7 , Shruthi Mohan  2 , Justyne E Ross  2 , Wolfgang Bergmeier  8 , Jorge Di Paola  9 ; ClinGen Platelet Disorder Variant Curation Expert Panel
Affiliations
Review

Glanzmann thrombasthenia: genetic basis and clinical correlates

Juliana Perez Botero et al. Haematologica. 2020 Apr.

Abstract

Glanzmann thrombasthenia (GT) is an autosomal recessive disorder of platelet aggregation caused by quantitative or qualitative defects in integrins αIIb and β3. These integrins are encoded by the ITGA2B and ITGB3 genes and form platelet glycoprotein (GP)IIb/IIIa, which acts as the principal platelet receptor for fibrinogen. Although there is variability in the clinical phenotype, most patients present with severe mucocutaneous bleeding at an early age. A classic pattern of abnormal platelet aggregation, platelet glycoprotein expression and molecular studies confirm the diagnosis. Management of bleeding is based on a combination of hemostatic agents including recombinant activated factor VII with or without platelet transfusions and antifibrinolytic agents. Refractory bleeding and platelet alloimmunization are common complications. In addition, pregnant patients pose unique management challenges. This review highlights clinical and molecular aspects in the approach to patients with GT, with particular emphasis on the significance of multidisciplinary care.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Typical laboratory phenotype in Glanzmann thrombasthenia (GT).
Figure 2.
Figure 2.
Diagnostic flow chart for the laboratory evaluation of a patient with suspected Glanzmann thrombasthenia (GT).
See this image and copyright information in PMC

References

    1. Commentary on and reprint of Glanzmann E, Hereditäre häemorrhagische thrombasthenie. Ein Beitrag zur Pathologie der Blutplättchen [Hereditary hemorrhagic thrombasthenia: A contribution on the pathology of blood platelets], in Jahrbuch für Kinderheilkunde (1918) 88:113–141. In: Lichtman MA, Spivak JL, Boxer LA, Shattil SJ, Henderson ES, eds. Hematology. San Diego: Academic Press, 2000:55–III.
    1. Caen J, Cousin C. [“In vivo” disorder of platelet adhesiveness in Willebrand’s disease and Glanzmann’s thrombasthenias. Trial interpretation]. Nouv Rev Fr Hematol. 1962;2:685–694. - PubMed
    1. Caen JP, Castaldi PA, Leclerc JC, et al. Congenital bleeding disorders with long bleeding time and normal platelet count: I. Glanzmann’s thrombasthenia (report of fifteen patients). Am J Med. 1966;41(1):4–26.
    1. Nurden AT, Caen JP. An abnormal platelet glycoprotein pattern in three cases of Glanzmann’s thrombasthenia. Br J Haematol. 1974;28(2):253–260. - PubMed
    1. Phillips DR, Agin PP. Platelet membrane defects in Glanzmann’s thrombasthenia. Evidence for decreased amounts of two major glycoproteins. J Clin Invest. 1977;60(3):535–545. - PMC - PubMed

Publication types

Substances